• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • News
    • Analyses
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
    • Scientific Presentations
  • Investors
    • Overview
    • News
    • Analyses
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Board and Management
    • The Share
    • Financial Reports
      • Financial Reports - English
      • Financial Reports – Swedish
      • Financial Calendar
    • Corporate Governance
    • General Meetings
    • IR Contact
  • Career
  • Contact
Home / Investors / Financial Reports
  • Overview
  • News
  • Analyses
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Board and Management
  • The Share
  • Financial Reports
    • Financial Reports - English
    • Financial Reports – Swedish
    • Financial Calendar
  • Corporate Governance
  • General Meetings
  • IR Contact

Financial Reports

The financial year for Alzinova follows the calendar year.  Financial reports are prepared in accordance with the Swedish Annual Accounts Act and the general recommendations of the Swedish Accounting Standards Board, and further presented according to the requirements from Nasdaq First North Grow Market.

en
  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB, Gemenskapens gata 9,  SE-431 53 Mölndal
info@alzinova.com

Follow us on

follow us on linkedin